StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

Investment analysts at StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock.

A number of other equities analysts also recently issued reports on CTLT. Barclays raised their price target on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Stephens reiterated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Finally, UBS Group reiterated a “neutral” rating and set a $63.50 target price (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $52.46.

Catalent Stock Performance

CTLT stock opened at $56.37 on Friday. The company has a market cap of $10.20 billion, a P/E ratio of -8.29, a price-to-earnings-growth ratio of 6.09 and a beta of 1.18. Catalent has a 1 year low of $31.45 and a 1 year high of $60.20. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The stock’s fifty day moving average price is $56.44 and its 200-day moving average price is $49.16.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business’s quarterly revenue was down 10.2% on a year-over-year basis. During the same quarter last year, the business earned $0.62 earnings per share. On average, equities analysts forecast that Catalent will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Catalent

Institutional investors and hedge funds have recently bought and sold shares of the business. Lindbrook Capital LLC raised its holdings in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares during the period. Gladius Capital Management LP bought a new stake in shares of Catalent in the third quarter worth about $28,000. Exchange Traded Concepts LLC bought a new stake in shares of Catalent in the third quarter worth about $31,000. GAMMA Investing LLC bought a new stake in shares of Catalent in the fourth quarter worth about $33,000. Finally, Cary Street Partners Investment Advisory LLC increased its holdings in shares of Catalent by 1,162.3% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after purchasing an additional 709 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.